Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2011
10/26/2011EP2379563A1 Gamma secretase modulators
10/26/2011EP2379562A1 Bicyclic pyranone derivatives as nicotinic acid receptor agonists
10/26/2011EP2379561A2 Mlk inhibitors and methods of use
10/26/2011EP2379559A2 Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
10/26/2011EP2379558A1 Novel heterocyclic compounds for use as metap-2 inhibitors
10/26/2011EP2379557A1 Amino pyrazole compound
10/26/2011EP2379556A1 Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
10/26/2011EP2379555A1 Purine compounds
10/26/2011EP2379553A1 Bicyclic compounds for the reduction of beta-amyloid production
10/26/2011EP2379552A1 Substituted bicyclic imidazole derivatives as gamma secretase modulators
10/26/2011EP2379551A1 Substituted pyrazolo [3, 4-b]pyridine compounds
10/26/2011EP2379550A1 Piperidine derivatives useful as orexin antagonists
10/26/2011EP2379549A1 7-azaindirubins, 7'azaindirubins, 7,7'-diazaindirubins and the corresponding 3'-oxime ether derivatives thereof, their production and use as a medicament
10/26/2011EP2379548A1 Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
10/26/2011EP2379546A1 Monocarbams
10/26/2011EP2379545A1 2- (piperidin-1-yl) -4-azolyl-thiazole-5-carboxylic acid derivatives against bacterial infections
10/26/2011EP2379542A1 Novel oxime derivatives
10/26/2011EP2379540A1 Dipeptoid prodrugs and the use thereof
10/26/2011EP2379539A1 Amino acid ester prodrugs and the use thereof
10/26/2011EP2379538A2 Heterocyclic compounds as phosphodiesterase inhibitors
10/26/2011EP2379535A1 7-phenoxychroman carboxylic acid derivatives
10/26/2011EP2379534A1 Heterocyclic antiviral compounds
10/26/2011EP2379533A1 N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity
10/26/2011EP2379532A1 Compounds useful for inhibiting chk1
10/26/2011EP2379530A1 Pyrimidine indole derivatives for treating cancer
10/26/2011EP2379529A1 Novel compounds
10/26/2011EP2379528A1 Protein kinase inhibitors
10/26/2011EP2379527A1 Pyrimidin- 2 -ylamino derivatives and their use to treat inflammation
10/26/2011EP2379525A1 Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
10/26/2011EP2379524A1 Serotonin 5-ht2b receptor inhibitors
10/26/2011EP2379523A1 4, 6-disubstituted 2-amino-pyrimidines as histamine h4 receptor modulators
10/26/2011EP2379521A1 Sulfamides as trpm8 modulators
10/26/2011EP2379520A2 Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
10/26/2011EP2379519A1 (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
10/26/2011EP2379518A1 Thiadiazole-substituted arylamides
10/26/2011EP2379517A1 Arylcyclopropylacetamide derivatives useful as glucokinase activators
10/26/2011EP2379516A1 1,3,4-oxadiazole derivatives and their uses to treat diabetes
10/26/2011EP2379513A1 Heteroaryl compounds useful as raf kinase inhibitors
10/26/2011EP2379511A1 Substituted diketopiperazine analogs for use as drug delivery agents
10/26/2011EP2379510A1 Quinazolinone compounds
10/26/2011EP2379507A1 Sulfonamide compounds for the treatment of respiratory disorders
10/26/2011EP2379506A1 Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
10/26/2011EP2379505A1 Modified chloroquines with single ring moiety or fused ring moiety
10/26/2011EP2379504A2 Coumarin-based compounds
10/26/2011EP2379502A2 Novel forms of eperisone
10/26/2011EP2379499A1 New salts
10/26/2011EP2379498A1 New polymorphic form of 1- (4- { l- ý (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino¨-ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
10/26/2011EP2379497A1 Hemifumarate salt of 1- ý4- ý1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl¨-2 -ethyl-benzyl¨-a zetidine-3-carboxylic acid
10/26/2011EP2379496A1 Sulfonamides as trpm8 modulators
10/26/2011EP2379493A1 Process for the preparation of asymmetrical bis(thiosemicarbazones)
10/26/2011EP2379492A1 Cyclohexanecarboxamide derivatives useful as inhibitors of cholesteryl ester transfer protein
10/26/2011EP2379490A1 Monohydrate of 4-({(4-carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]-amino}methyl)benzoic acid
10/26/2011EP2379489A1 Modification i of 4-({4-carboxybutyl)ý2-(2-{ý4-(2-phenylethyl)benzyl¨oxy}phenyl)ethyl¨-amino}methyl)benzoic acid
10/26/2011EP2379484A1 Polyunsaturated fatty acid and diol ester as an anti-acne agent
10/26/2011EP2379175A1 A process for preparation of hexadecyl cis-9-tetradecenoate and hexadecyl cis-10-tetradecenoate
10/26/2011EP2379174A1 Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
10/26/2011EP2379173A1 Anti-snoring composition containing a thermogelling polymer
10/26/2011EP2379111A1 Narcotic drug formulations with decreased abuse potential
10/26/2011EP2379110A1 Formulation for the buccal transmucosal administration of setrons
10/26/2011EP2379109A1 Combination of photodynamic therapy and anti-vegf agents in the treatment of unwanted choroidal neovasculature
10/26/2011EP2379102A1 Fibcd1 for the prevention and treatment of diseases
10/26/2011EP2379100A1 Method for treating hyperglycemia with glp-1
10/26/2011EP2379099A1 Method for the prophylaxis or treatment of flushing
10/26/2011EP2379090A1 Improved animal treatment
10/26/2011EP2379084A2 Modulation of factor 11 expression
10/26/2011EP2379083A2 Extended dicer substrate agents and methods for the specific inhibition of gene expression
10/26/2011EP2379082A2 Acne treatment powder foundation
10/26/2011EP2379081A1 Treatment of diarrhoea
10/26/2011EP2379080A1 Pirenzepine as otoprotective agent
10/26/2011EP2379079A1 Pharmaceutical formulations comprising voriconazole and processes for preparation thereof
10/26/2011EP2379078A2 Topical formulations of flap inhibitors for administration to an eye
10/26/2011EP2379077A2 Pharmaceutical composition
10/26/2011EP2379076A1 Phosphodiesterase inhibitors and uses thereof
10/26/2011EP2379075A1 Triazole derivatives for treatment of alzheimer's disease
10/26/2011EP2379074A1 Macrolactone derivatives, method for the production thereof and use thereof for the treatment of cancer
10/26/2011EP2379073A2 Methods for treating or preventing cancer and neurodegenerative diseases
10/26/2011EP2379071A2 Novel aliphatically substituted pyrazolopyridines, and the use thereof
10/26/2011EP2379070A1 Stable water-based topical pharmaceutical creams and methods of making and using same
10/26/2011EP2379069A1 Dosage regimen of an s1p receptor agonist
10/26/2011EP2379068A1 Compounds effective against cancer
10/26/2011EP2379067A1 Dosage regimen for a s1p receptor agonist
10/26/2011EP2379066A1 Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases
10/26/2011EP2379065A2 Capecitabine rapidly disintegrating tablets
10/26/2011EP2379063A1 Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
10/26/2011EP2379062A1 Pharmaceutical composition comprising one or more fumaric acid esters
10/26/2011EP2379061A2 Precompacted fast-disintegrating formulations of compounds with a low oral bioavailability
10/26/2011EP2379060A2 Extended-release pharmaceutical formulations
10/26/2011EP2379059A1 Controlled releasing composition
10/26/2011EP2379058A1 Retigabine tablets, preferably having modified release
10/26/2011EP2379057A1 Phenylephrine formulations with improved stability
10/26/2011EP2379056A2 Solid pharmaceutical composition comprising at least one stabilizing agent
10/26/2011EP2379055A1 Method of making sustained release microparticles
10/26/2011EP2379054A1 Formulation for delivering lipid-lowering drugs by oral transmucosal administration
10/26/2011EP2379053A1 Prophylactic/therapeutic agent for cancer
10/26/2011EP2379006A1 Minimal tissue attachment implantable materials
10/26/2011EP2378887A2 Combined disinfection and decontamination agent having increased effectivity
10/26/2011EP2378886A1 Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
10/26/2011EP2378884A2 Use of cationic surfactants as acaricidal agents
10/26/2011EP2378883A2 Zaleplon gastroretentive drug delivery system
10/26/2011EP2378879A1 Triazole derivatives for treatment of alzheimer's disease
1 ... 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 ... 7860